Why Medication Content Needs a Clinician's Eye

A confident sentence: "This medicine is generally safe and well tolerated, with most people experiencing no problems." Nothing in it is grammatically wrong. A skilled copy editor would read straight past it. A pharmacist would stop dead, because the sentence has quietly skipped the two people for whom the drug is dangerous, the one common interaction that lands patients in hospital, and the populations the trials never enrolled.

That is the problem with medication content in a single line. The errors are not errors of language, which is what most editing catches. They are errors of clinical context, which sit invisible to anyone without a pharmacology-shaped mind. A medicines article can be fluent, well structured, factually defensible sentence by sentence, and still be the most dangerous thing a publisher puts out that month.

Why this category fails differently

General health content fails through omission and overclaiming — important enough, and the subject of its own conversation. Medication content fails through those plus a layer of hazards that only exist because the subject is a regulated substance with a licence, a dose, and a list of people it can harm.

A condition explainer that gets something slightly wrong tends to mislead. A medicines article that gets something slightly wrong can change what a reader puts in their mouth. The stakes are not abstractly higher; they are concretely higher, and they concentrate in a handful of predictable places.

The failure modes, named

Interactions. Drugs do not act in isolation; readers do not take them in isolation. A piece describing a medicine as benign may be describing it accurately for someone on nothing else — and inaccurately for the large slice of readers also taking an anticoagulant, an antidepressant, the contraceptive pill, or an over-the-counter painkiller they would never think to mention. Interaction is the single most common thing lay-written medication content omits, because you cannot omit what you never knew existed.

Contraindications. Most medicines have a population they must not be given to — pregnancy, a specific organ impairment, a previous reaction, a coexisting condition. "Generally safe" is a phrase that quietly erases that population. The clinical edit is almost mechanical: every reassuring generalisation about a drug needs the exceptions named, because the exceptions are precisely the readers who come to harm.

The off-label blur. A medicine licensed for one use is often discussed online for another — sometimes reasonably, sometimes not. Content frequently slides between the two without ever signalling the shift, leaving a reader unable to tell whether they are reading about an approved use or an experiment. The licensed-versus-unlicensed distinction is not pedantry; under UK rules it governs what can lawfully be said about a medicine and to whom.

Populations excluded from trials. Efficacy figures come from trial populations, which are systematically tidier than the public: younger, with fewer coexisting conditions, on fewer other drugs, more often male, rarely frail or elderly. An article that reports a trial result as a universal promise has performed a sleight of hand a clinician sees instantly — the gap between worked in this carefully selected group and will work for you is where a great deal of medication writing quietly overreaches.

Dosing and the missing specifics. Numbers carry weight that prose does not, and wrong numbers in a medicines article are not typos; they are hazards. A clinical review treats every dose, frequency and threshold as a claim to be verified against a current formulary, not a detail to be trusted because it reads plausibly.

The regulatory layer most editors never see

There is a second reason medication content needs clinical eyes, and it is not strictly medical: it is legal. In the UK, what may be said about a medicine is governed, not merely advised. The MHRA's Blue Guide sets out the rules on advertising medicines, including the bright line between providing balanced information and promoting a product — and the prohibition on advertising prescription-only medicines to the public at all. The ABPI Code governs how the pharmaceutical industry communicates. These frameworks exist because medication content is exactly the place where information and promotion blur, often without the writer intending it.

A clinician who works in this space reads a medicines article with that overlay running: is this informing or is it selling, is this claim something that can lawfully be said to a general reader, has a prescription-only medicine been described in a way that functions as an advert. A lay editor optimising for clarity and engagement is, with the best intentions, working on a different problem entirely — and the gap between those two jobs is where regulatory trouble lives.

A checklist editors can actually use

None of this requires a medical degree to apply, once someone with one has built the questions. A working pass over any medication article should ask:

• Are the common side effects named, and is the rare serious one named separately rather than averaged away?
• Are contraindications and major interactions stated, including the ordinary ones — alcohol, common over-the-counter drugs, the contraceptive pill?
• Is every dose, frequency and threshold sourced to a current formulary, not to the previous draft?
• Does the piece keep licensed and off-label uses distinct, and never let a prescription-only medicine read as an advertisement?
• Is there a clear line back to a prescriber or pharmacist for the decision, rather than an implied green light from the page?
• Are trial results framed as what they are — results in a defined population — rather than promises to every reader?

A piece that clears all six is not guaranteed correct. A piece that fails any of them is, with near certainty, missing something a patient would have wanted to know.

Practical takeaways

• Medication content fails in places general health content does not: interactions, contraindications, the off-label blur, and trial populations that do not resemble the reader.
• "Generally safe and well tolerated" is the single most reliable sign that the dangerous specifics have been edited out.
• Doses, frequencies and thresholds are claims, not details — each needs checking against a current formulary.
• There is a legal layer, not only a clinical one: UK rules govern what may be said about medicines, and where information becomes promotion.
• A six-question editorial pass catches most of it — but the questions have to be built by someone who knows where medicines actually go wrong.

What this doesn't mean

It doesn't mean lay editors add nothing to medication content; clarity, structure and plain language matter enormously, and clinicians are frequently worse at them. The argument is narrower: clinical and copy review are different jobs, and a medicines article needs both. One makes the writing readable. The other makes it safe and lawful. Skipping the second because the first went well is how fluent, dangerous content gets published.

A closing thought

The most unsettling medication articles are not the obviously bad ones — those announce themselves. They are the polished, plausible, professionally written pieces in which everything reads correctly and the one missing interaction never made it onto the page. You cannot copy-edit your way to catching that. It takes someone who has watched what happens when the missing line was needed.

Further reading and sources

• MHRA — Blue Guide: Advertising and Promotion of Medicines in the UK
• British National Formulary (BNF) — the currency benchmark for UK dosing and interactions
• ABPI Code of Practice for the Pharmaceutical Industry
• Patient Information Forum — PIF TICK criteria for trustworthy health information
• General Medical Council — Good Medical Practice (honesty and clarity in communication)